Can you provide the last earnings date for CELLDEX THERAPEUTICS INC?
CELLDEX THERAPEUTICS INC (CLDX) last reported earnings on 2/25/2026.
NASDAQ:CLDX • US15117B2025
Past quarterly earnings results for CELLDEX THERAPEUTICS INC (CLDX), including EPS and revenue actuals, analyst estimates, and surprise percentages. This page focuses on historical performance (not forecasts).
EPS & Revenue History (in USD): Actual vs estimated values, surprises, q2q growth and acceleration numbers quarterly history.
| Quarter | EPS | EPS Est | EPS Surprise | EPS Q2Q | Revenue | Revenue Est | Revenue Surprise | Revenue Q2Q |
|---|---|---|---|---|---|---|---|---|
| Q4 2025 | -1.22 | -1.03 | -18.58% | -71.83% | 121K | 1.506M | -91.97% | -89.70% |
| Q3 2025 | -1.01 | -0.92 | -9.94% | -57.81% | 1.005M | -100.00% | -100.00% | |
| Q2 2025 | -0.85 | -0.87 | 2.62% | -57.41% | 730K | 1.027M | -28.92% | -70.78% |
| Q1 2025 | -0.81 | -0.77 | -5.18% | -44.64% | 695K | 1.067M | -34.86% | 345.51% |
| Q4 2024 | -0.71 | -0.75 | 5.21% | 14.46% | 1.175M | 1.138M | 3.25% | -71.56% |
| Q3 2024 | -0.64 | -0.69 | 6.71% | 20.99% | 3.191M | 844.866K | 277.69% | 110.35% |
| Q2 2024 | -0.54 | -0.60 | 9.93% | 16.92% | 2.498M | 836.839K | 198.50% | 832.09% |
| Q1 2024 | -0.56 | -0.71 | 20.89% | 9.68% | 156K | 934.065K | -83.30% | -83.87% |
| Q4 2023 | -0.83 | -0.76 | -9.41% | -48.21% | 4.132M | 859.717K | 380.62% | 156.65% |
| Q3 2023 | -0.81 | -0.69 | -17.03% | -42.11% | 1.517M | 586.837K | 158.50% | 270.00% |
| Q2 2023 | -0.65 | -0.68 | 4.41% | -10.17% | 268K | 538.56K | -50.24% | 67.50% |
| Q1 2023 | -0.62 | -0.64 | 3.82% | -26.53% | 967K | 418.2K | 131.23% | 468.82% |
| Q4 2022 | -0.56 | -0.60 | 6.95% | -30.23% | 1.61M | 269.28K | 497.89% | 387.88% |
| Q3 2022 | -0.57 | -0.59 | 3.09% | -26.67% | 410K | 367.2K | 11.66% | 173.33% |
| Q2 2022 | -0.59 | -0.52 | -13.42% | -73.53% | 160K | 408K | -60.78% | -95.40% |
| Q1 2022 | -0.49 | -0.46 | -5.81% | -16.67% | 170K | 571.2K | -70.24% | -75.36% |
| Q4 2021 | -0.43 | -0.43 | -1.18% | 21.82% | 330K | 1.057M | -68.78% | -91.29% |
| Q3 2021 | -0.45 | -0.37 | -22.55% | -25.00% | 150K | 1.246M | -87.96% | -77.61% |
| Q2 2021 | -0.34 | -0.41 | 16.67% | 32.00% | 3.48M | 656.197K | 430.33% | 1,350.00% |
| Q1 2021 | -0.42 | -0.39 | -8.36% | 42.47% | 690K | 816K | -15.44% | -74.73% |
| Q4 2020 | -0.55 | -0.37 | -47.06% | - | 3.79M | 612K | 519.28% | - |
| Q3 2020 | -0.36 | -0.37 | 1.96% | - | 670K | 402.9K | 66.29% | - |
| Q2 2020 | -0.50 | -0.59 | 15.48% | - | 240K | 816K | -70.59% | - |
| Q1 2020 | -0.73 | -0.72 | -0.80% | - | 2.73M | 1.01M | 170.30% | - |
Notes
CELLDEX THERAPEUTICS INC (CLDX) last reported earnings on 2/25/2026.
CELLDEX THERAPEUTICS INC (CLDX) missed EPS estimates and missed revenue estimates in the most recent quarter.
In the last 4 quarters, CELLDEX THERAPEUTICS INC (CLDX) has beaten EPS estimates in 1 out of 4 releases.